311 related articles for article (PubMed ID: 16166615)
41. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.
Wielpütz MO; Puderbach M; Kopp-Schneider A; Stahl M; Fritzsching E; Sommerburg O; Ley S; Sumkauskaite M; Biederer J; Kauczor HU; Eichinger M; Mall MA
Am J Respir Crit Care Med; 2014 Apr; 189(8):956-65. PubMed ID: 24564281
[TBL] [Abstract][Full Text] [Related]
42. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.
Kraynack NC; Gothard MD; Falletta LM; McBride JT
Pediatr Pulmonol; 2011 Sep; 46(9):870-81. PubMed ID: 21465675
[TBL] [Abstract][Full Text] [Related]
43. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis.
Kapur N; Masters IB; Morris PS; Galligan J; Ware R; Chang AB
Pediatr Pulmonol; 2012 Jan; 47(1):68-75. PubMed ID: 21830316
[TBL] [Abstract][Full Text] [Related]
44. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.
Dasenbrook EC; Merlo CA; Diener-West M; Lechtzin N; Boyle MP
Am J Respir Crit Care Med; 2008 Oct; 178(8):814-21. PubMed ID: 18669817
[TBL] [Abstract][Full Text] [Related]
45. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
Tunney MM; Field TR; Moriarty TF; Patrick S; Doering G; Muhlebach MS; Wolfgang MC; Boucher R; Gilpin DF; McDowell A; Elborn JS
Am J Respir Crit Care Med; 2008 May; 177(9):995-1001. PubMed ID: 18263800
[TBL] [Abstract][Full Text] [Related]
46. Cellular proteolysis and systemic inflammation during exacerbation in cystic fibrosis.
Ionescu AA; Nixon LS; Shale DJ
J Cyst Fibros; 2004 Dec; 3(4):253-8. PubMed ID: 15698944
[TBL] [Abstract][Full Text] [Related]
47. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
[TBL] [Abstract][Full Text] [Related]
48. Safety and use of sputum induction in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Shute JK; Bush A
Pediatr Pulmonol; 2003 Apr; 35(4):309-13. PubMed ID: 12629630
[TBL] [Abstract][Full Text] [Related]
49. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum.
Hansen G; Schuster A; Zubrod C; Wahn V
Respiration; 1995; 62(3):117-24. PubMed ID: 7569330
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.
Konstan MW; Morgan WJ; Butler SM; Pasta DJ; Craib ML; Silva SJ; Stokes DC; Wohl ME; Wagener JS; Regelmann WE; Johnson CA;
J Pediatr; 2007 Aug; 151(2):134-9, 139.e1. PubMed ID: 17643762
[TBL] [Abstract][Full Text] [Related]
51. Change in IgG and evolution of lung function in children with cystic fibrosis.
Proesmans M; Els C; Vermeulen F; De Boeck K
J Cyst Fibros; 2011 Mar; 10(2):128-31. PubMed ID: 21220215
[TBL] [Abstract][Full Text] [Related]
52. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
53. Longitudinal monitoring of pediatric cystic fibrosis lung disease using nitrite in exhaled breath condensate.
Horak F; Moeller A; Singer F; Straub D; Höller B; Helbich TH; Schneider B; Eichler I; Wildhaber JH; Hall GL
Pediatr Pulmonol; 2007 Dec; 42(12):1198-206. PubMed ID: 17968999
[TBL] [Abstract][Full Text] [Related]
54. alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis.
O'Connor CM; Gaffney K; Keane J; Southey A; Byrne N; O'Mahoney S; Fitzgerald MX
Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1665-70. PubMed ID: 8256917
[TBL] [Abstract][Full Text] [Related]
55. Induced sputum nitrites correlate with FEV1 in children with cystic fibrosis.
Anil N; Singh M; Rajwanshi A; Vohra H
Acta Paediatr; 2010 May; 99(5):711-714. PubMed ID: 20096026
[TBL] [Abstract][Full Text] [Related]
56. Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis.
Chotirmall SH; O'Donoghue E; Bennett K; Gunaratnam C; O'Neill SJ; McElvaney NG
Chest; 2010 Nov; 138(5):1186-95. PubMed ID: 20472859
[TBL] [Abstract][Full Text] [Related]
57. Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices.
Hurst JR; Perera WR; Wilkinson TM; Donaldson GC; Wedzicha JA
Proc Am Thorac Soc; 2006 Aug; 3(6):481-2. PubMed ID: 16921117
[No Abstract] [Full Text] [Related]
58. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.
Ratjen F; Waters V; Klingel M; McDonald N; Dell S; Leahy TR; Yau Y; Grasemann H
Eur Respir J; 2016 Mar; 47(3):829-36. PubMed ID: 26585432
[TBL] [Abstract][Full Text] [Related]
59. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis.
Flight WG; Bright-Thomas RJ; Tilston P; Mutton KJ; Guiver M; Morris J; Webb AK; Jones AM
Thorax; 2014 Mar; 69(3):247-53. PubMed ID: 24127019
[TBL] [Abstract][Full Text] [Related]
60. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Sanders DB; Hoffman LR; Emerson J; Gibson RL; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2010 Feb; 45(2):127-34. PubMed ID: 20054859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
